Table 1.
switch levela | no. | name | ON switchb | OFF switchc | origin | effectord | applications | references |
---|---|---|---|---|---|---|---|---|
transcriptional switches | ||||||||
1 | ABA | yes | no | Arabidopsis thaliana, yeast | abscisic acid | gene therapy, experimental tool to control diverse cellular activities in vivo | [19] | |
2 | AIR | yes | no | Aspergillus nidulans | acetaldehyde | gas-adjustable transgene expression, biopharmaceutical manufacturing | [20] | |
3 | ART | yes | no | Chlamydia pneumoniae | l-arginine | biopharmaceutical manufacturing, gene therapy | [21] | |
4 | BEARON, BEAROFF | yes | yes | Campylobacter jejuni | bile acid | gene- and cell-based therapies | [22] | |
5 | BirA-tTA | no | yes | Escherichia coli | biotin (vitamin H) | biopharmaceutical manufacturing, cell therapy | [23] | |
6 | BIT | yes | no | Escherichia coli | biotin (vitamin H) | gene therapy, tissue engineering, biopharmaceutical manufacturing | [24] | |
7 | Cry2-CIB1 | yes | no | Arabidopsis thaliana, yeast | blue light | protein translocation, transcription control, Cre-mediated DNA recombination using light | [25] | |
8 | CTA, CTS | yes | yes | Comamonas testosteroni, Homo sapiens | food additives (benzoate, vanillate) | gene- and cell-based therapy | [26] | |
9 | cTA, rcTA | yes | yes | Pseudomonas putida | cumate | regulation of gene expression level and duration | [27] | |
10 | Ecdysone | yes | no | Homo sapiens, Drosophila melanogaster | Ecdysone | transient inducible expression, gene therapy | [28] | |
11 | EcR:RXR | yes | no | Homo sapiens, Locusta migratoria | ecdysone | ligand-dependent induction of reporter gene, gene therapy | [29] | |
12 | electro-genetic | yes | no | Aspergillus nidulans | electricity, acetaldehyde | electric power-adjustable transcription control; mammalian cell-based control of microelectronic circuits | [30] | |
13 | ER-p65-ZF | yes | no | Homo sapiens, yeast | 4,4′-dyhydroxybenzil | generating a wide array of orthogonal gene switches | [31] | |
14 | E.REX | yes | yes | Escherichia coli | erythromycin | gene therapy, tissue engineering, in vivo gene-function analyses, drug discovery, biopharmaceutical manufacturing | [32] | |
15 | EthR | no | yes | Mycobacterium tuberculosis | 2-phenylethyl-butyrate | drug discovery | [33] | |
16 | GAL4-ER | yes | yes | yeast, Homo sapiens | oestrogen, 4-hydroxytamoxifen | regulating heterologous genes, identifying Fos (oncogene) targets | [34] | |
17 | GAL4-hPR | yes | yes | yeast, Homo sapiens | mifepristone | positive and negative regulation of gene expression, also in vivo | [35,36] | |
18 | GAL4-Raps | yes | yes | yeast, Homo sapiens | rapamycin and rapamycin derivatives | targeted gene expression control | [37] | |
19 | GAL4-TR | yes | no | yeast, Homo sapiens | thyroid hormone | study nuclear receptor signalling | [38] | |
20 | GyrB | yes | yes | Escherichia coli | coumermycin, novobiocin | rapid regulation of gene expression | [39] | |
21 | HEA-3 | yes | no | Homo sapiens | 4-hydroxytamoxifen | gene therapy | [40] | |
22 | Intramer | no | yes | synthetic SELEX-derived aptamers | theophylline | controlling transgene expression, construction of complex gene networks | [41] | |
23 | LacI | yes | no | Escherichia coli | IPTG | reversible regulation of gene expression, predictable levels of de-repressed gene expression | [42–46] | |
24 | LAD | yes | no | Arabidopsis thaliana, yeast | blue light | light-controlled gene expression regulation; protein hetero- and homo-dimerization induced by light | [47] | |
25 | LightOn | yes | no | Neurospora crassa, yeast | blue light | light-switchable transcription control | [48] | |
26 | NICE | yes | yes | Arthrobacter nicotinovorans | 6-hydroxynicotine | therapeutic cell engineering, biopharmaceutical manufacturing | [49] | |
27 | PPAR* | yes | no | Homo sapiens | rosiglitazone | gene therapy | [50] | |
28 | PEACE | no | yes | Pseudomonas putida | flavonoids (e.g. phloretin) | biopharmaceutical manufacturing, gene- and cell-based therapies | [51] | |
29 | PIT | yes | yes | Streptomyces coelicolor | pristinamycin I, virginiamycin | compatible with the Tet-OFF system, thus two different gene activities can be controlled in the same cell | [12] | |
30 | REDOX | no | yes | Streptomyces coelicolor | NADH | process development, biopharmaceutical manufacturing | [52] | |
31 | QuoRex | yes | yes | Streptomyces coelicolor, Streptomyces pristinaespiralis | butyrolactones (e.g. SCB1) | small molecule-adjustable gene control systems for clinical application | [53] | |
32 | ST-TA | yes | yes | Streptomyces coelicolor, Escherichia coli, Herpes simplex | γ-butyrolactone, tetracycline | Design of therapeutic gene circuits for gene and cell-based therapies | [54] | |
33 | TIGR | no | yes | Streptomyces albus | temperature | temperature-inducible gene regulation | [55] | |
34 | TraR | yes | no | Agrobacterium tumefaciens | N-(3-oxo-octanoyl)homoserine lactone | versatile gene expression control | [56] | |
35 | TET-OFF, TET-ON | yes | yes | Escherichia coli, Herpes simplex | tetracycline, doxycycline | reversible and tight gene expression control | [11,57] | |
36 | TRT | yes | no | Chlamydia trachomatis | l-tryptophan | synthetic bidirectional communication between mammalian cells | [58] | |
37 | UREX | yes | no | Deinococcus radiodurans | uric acid | self-sufficient control of pathologic metabolites, gene- and cell-based therapies | [59] | |
38 | VAC | yes | yes | Caulobacter crescentus | vanillic acid | biopharmaceutical manufacturing, gene- and cell-based therapies | [60] | |
39 | ZF-ER, ZF-RXR/EcR | yes | yes | Mus musculus, Homo sapiens, Drosophila melanogaster | 4-hydroxytamoxifen, ponasterone-A | spatio-temporal control of gene expression, genomic and proteomic research, gene therapy | [61] | |
40 | ZF-Raps | yes | no | Homo sapiens | rapamycin | gene expression control, gene therapy | [62] | |
41 | ZF switches | yes | no | Mus musculus, Homo sapiens, Drosophila melanogaster | 4-hydroxytamoxifen, mifepristone | study of gene function, alteration of phenotypes of cells or organisms | [63] | |
42 | ZF(TF)s | yes | no | Xenopus laevis, Homo sapiens | ethyl-4-hydroxybenzoate, propyl-4-hydroxybenzoate | genomic and proteomic research, gene therapy | [64] | |
post-transcriptional switches | ||||||||
1 | aptamer RNAi | yes | no | synthetic SELEX-derived aptamer | theophylline | regulation of gene expression by small molecules without engineered proteins | [65] | |
2 | aptamer RNAi | no | yes | synthetic SELEX-derived aptamer | theophylline | construction of conditional RNAi systems | [66] | |
3 | aptamer RNAi miRNA | yes | no | synthetic SELEX-derived aptamer | theophylline, tetracycline, hypoxanthine | probing and programming of cellular function | [67] | |
4 | aptamer Splicing | yes | yes | Homo sapiens, MS2 bacteriophage | MS2, p65, p50, b-catenin | programmable sensing-actuation devices for autonomous cell behaviour control | [68] | |
5 | aptazyme | no | yes | synthetic SELEX-derived aptamer, Schistosoma mansoni | theophylline | regulation of therapeutic gene expression | [69] | |
6 | replicon CytTS | yes | no | Sindbis virus | temperature | expression of toxic proteins, bioprocess engineering | [70] | |
7 | TET-OFF-shRNA, TET-ON-shRNA | yes | yes | Escherichia coli, Herpes simplex, Homo sapiens | doxycycline | basic or translational research, development of gene-based therapeutics | [71] | |
8 | theo aptamer | no | yes | synthetic SELEX-derived aptamer | theophylline | basic, biotechnological, and biomedical research | [72] | |
9 | 3′ UTR aptazyme | yes | no | synthetic SELEX-derived aptamers, tobacco ringspot virus | theophylline, tetracycline | functional response regulation, gene and cellular therapy | [73] | |
10 | 5′ UTR aptazyme | no | yes | synthetic SELEX-derived aptamer, Schistosoma mansoni | theophylline | control of gene expression, gene therapy | [74] | |
translational switches | ||||||||
1 | Hoechst aptamer | no | yes | synthetic RNA sequence | Hoechst dyes | translational gene regulation, biology and medical research | [75] | |
2 | H23 aptamer | no | yes | Archaeoglobus fulgidus | L7Ae, L7KK | gene expression regulation, construction of a NOR gate | [76] | |
3 | L7Ae aptamer | yes | yes | Archaeoglobus fulgidus | L7Ae | detection, repair or rewiring of intrinsic cellular defects, characterization of complex circuits | [77] | |
4 | MS2 aptamer | no | yes | MS2 bacteriophage | MS2 | study RNA–protein interactions, clone RNA-binding proteins | [78] | |
post-translational switches | ||||||||
1 | AID | no | yes | Arabidopsis thaliana, Oryza sativa, Gossypium hirsutum | auxins (e.g. IAA) | control protein expression and study protein function | [79] | |
2 | ER DD | no | yes | Homo sapiens | CMP8, 4-hydroxytamoxifen | regulate the intracellular concentration of any protein | [80] | |
3 | FM | yes | no | Homo sapiens | AP21998 | delivery of polypeptides that require rapid and regulated delivery | [81] | |
4 | HaloTag | no | yes | Rhodococcus sp. RHA1 | HyT13 | validating potential drug targets in disease models | [82,83] | |
5 | HDV-aptazyme | no | yes | hepatitis delta virus | theophylline, guanine | dynamic range of gene regulation | [84] | |
6 | PROTAC | no | yes | Homo sapiens | proteolysis targeting chimeric molecules (PROTACS) | chemical knockouts, control of protein function | [85] | |
7 | shield DD | yes | no | Homo sapiens | shields (e.g. Shld1) | conditional control of proteins levels | [86] | |
8 | shield LID | no | yes | Homo sapiens | shields (e.g. Shld1) | conditional control of proteins levels | [87] | |
9 | TMP DD | yes | no | Escherichia coli | trimethoprim (TMP) | tuneable regulation of protein expression in the mammalian central nervous system | [88] |
aLevel of gene expression where the switching occurs.
bON switchability by an effector; other than removing the effector which confers the OFF state.
cOFF switchability by an effector; other than removing the effector which confers the ON state.
dA ligand or other physical stimuli (e.g. temperature, electromagnetic radiation, electricity) which stabilizes the switch either in its ON or OFF state.